Midatech Pharma (AIM:MTPH) - Share price, News & Analysis

MTPH fundamental analysis
Snowflake Score
Valuation	2/6
Future Growth	0/6
Past Performance	0/6
Financial Health	6/6
Dividends	0/6

MTPH Stock Overview

Midatech Pharma plc, a drug delivery technology company, focuses on the research and development of medicines in the United Kingdom, rest of Europe, and internationally.

Risk Analysis

Earnings have declined by 0.9% per year over past 5 years

Highly volatile share price over the past 3 months

Shareholders have been substantially diluted in the past year

Makes less than USD$1m in revenue (£578K)

+ 1 more risk

Midatech Pharma Competitors

ReNeuron Group

AIM:RENE

UK£15.8m

ProBiotix

OFEX:PBX

UK£26.2m

Destiny Pharma

AIM:DEST

UK£30.1m

Tissue Regenix Group

AIM:TRX

UK£31.6m

Price History & Performance

Summary of all time highs, changes and price drops for Midatech Pharma
Historical stock prices
Current Share Price	UK£0.087
52 Week High	UK£0.30
52 Week Low	UK£0.082
Beta	1.54
1 Month Change	-14.63%
3 Month Change	-28.57%
1 Year Change	-70.09%
3 Year Change	-91.42%
5 Year Change	-99.58%
Change since IPO	-99.84%

Shareholder Returns

	MTPH	GB Biotechs	GB Market
7D	-5.4%	1.2%	1.4%
1Y	-70.1%	-41.7%	-9.5%

Return vs Industry: MTPH underperformed the UK Biotechs industry which returned -40.8% over the past year.

Return vs Market: MTPH underperformed the UK Market which returned -6.7% over the past year.

Price Volatility

Is MTPH's price volatile compared to industry and market?
MTPH volatility
MTPH Average Weekly Movement	10.7%
Biotechs Industry Average Movement	6.6%
Market Average Movement	5.4%
10% most volatile stocks in GB Market	10.6%
10% least volatile stocks in GB Market	2.8%

Stable Share Price: MTPH is more volatile than 90% of UK stocks over the past 3 months, typically moving +/- 11% a week.

Volatility Over Time: MTPH's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of UK stocks.

About the Company

Founded	Employees	CEO	Website
2000	20	Stephen Stamp	https://www.midatechpharma.com

Midatech Pharma plc, a drug delivery technology company, focuses on the research and development of medicines in the United Kingdom, rest of Europe, and internationally. The company is developing MTX110, a direct delivery treatment for diffuse intrinsic pontine glioma, medulloblastomas, and glioblastoma multiforme; MTX114, an immuno-suppressant for topical application in psoriasis; MTD211, a long-acting formulation of brexpiprazole for the treatment of schizophrenia and adjunctive treatment of major depressive disorder; and MTD219, a long-acting formulation of tacrolimus used to lower the risk of organ transplant rejection. It also offers drug delivery platforms, such as Q-Sphera, a polymer microsphere microtechnology used for sustained release drug delivery; MidaSolve, an oligosaccharide nanotechnology used to solubilize drugs so that they can be administered in liquid form directly and locally into tumors; and MidaCore, a gold nanoparticle used for targeting sites of disease by using chemotherapeutic agents or immunotherapeutic agents.

Midatech Pharma Fundamentals Summary

How do Midatech Pharma's earnings and revenue compare to its market cap?
MTPH fundamental statistics
Market Cap	UK£8.62m
Earnings (TTM)	-UK£5.46m
Revenue (TTM)	UK£578.00k

14.9x

P/S Ratio

-1.6x

P/E Ratio

Is MTPH overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report
MTPH income statement (TTM)
Revenue	UK£578.00k
Cost of Revenue	UK£4.65m
Gross Profit	-UK£4.08m
Other Expenses	UK£1.38m
Earnings	-UK£5.46m

Last Reported Earnings

Dec 31, 2021

Next Earnings Date

n/a

Earnings per share (EPS)	-0.055
Gross Margin	-705.19%
Net Profit Margin	-944.64%
Debt/Equity Ratio	0%

How did MTPH perform over the long term?

See historical performance and comparison

We’ve recently updated our valuation analysis.

Valuation

Is MTPH undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
PEG Ratio

Key Valuation Metric

Which metric is best to use when looking at relative valuation for MTPH?

Other financial metrics that can be useful for relative valuation.

The above table shows the n/a ratio for MTPH. This is calculated by dividing MTPH's market cap by their current preferred multiple.
What is MTPH's n/a Ratio?
n/a Ratio	0x
n/a	n/a
Market Cap	UK£8.62m

MTPH key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	n/a
Enterprise Value/EBITDA	n/a
PEG Ratio	n/a

Price to Sales Ratio vs Peers

How does MTPH's PS Ratio compare to its peers?

MTPH PS Ratio vs Peers

The above table shows the PS ratio for MTPH vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	PS	Estimated Growth	Market Cap
Peer Average	78.6x
RENE ReNeuron Group	57.8x	77.7%	UK£15.8m
PBX ProBiotix	31.9x	n/a	UK£26.2m
DEST Destiny Pharma	222.8x	n/a	UK£30.1m
TRX Tissue Regenix Group	1.9x	27.2%	UK£31.6m
MTPH Midatech Pharma	14.9x	n/a	UK£8.6m

Forward PS

Price-To-Sales vs Peers: MTPH is good value based on its Price-To-Sales Ratio (14.9x) compared to the peer average (78.6x).

Price to Earnings Ratio vs Industry

How does MTPH's PE Ratio compare vs other companies in the GB Biotechs Industry?

Price-To-Sales vs Industry: MTPH is good value based on its Price-To-Sales Ratio (14.9x) compared to the UK Biotechs industry average (18.3x)

Price to Sales Ratio vs Fair Ratio

What is MTPH's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

MTPH PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio	14.9x
Fair PS Ratio	n/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate MTPH's Price-To-Sales Fair Ratio for valuation analysis.

Share Price vs Fair Value

What is the Fair Price of MTPH when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate MTPH's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate MTPH's fair value for valuation analysis.

Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate MTPH's PEG Ratio to determine if it is good value.

Discover undervalued companies

Future Growth

How is Midatech Pharma forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

Future Growth Score

0/6

Future Growth Score 0/6

Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Future ROE

17.5%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Midatech Pharma has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.

Discover growth companies

Examine Midatech Pharma's financial health to determine how well-positioned it is against times of financial stress by looking at its level of debt over time and how much cash it has left.
Midatech Pharma competitive advantages and company strategy can generally be found in its financial reports archived here.

Past Performance

How has Midatech Pharma performed over the past 5 years?

Past Performance Score

0/6

Past Performance Score 0/6

Quality Earnings
Growing Profit Margin
Earnings Trend
Accelerating Growth
Earnings vs Industry
High ROE

-0.9%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: MTPH is currently unprofitable.

Growing Profit Margin: MTPH is currently unprofitable.

Past Earnings Growth Analysis

Earnings Trend: MTPH is unprofitable, and losses have increased over the past 5 years at a rate of 0.9% per year.

Accelerating Growth: Unable to compare MTPH's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: MTPH is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-8.4%).

Return on Equity

High ROE: MTPH has a negative Return on Equity (-52.24%), as it is currently unprofitable.

Discover strong past performing companies

Financial Health

How is Midatech Pharma's financial position?

Financial Health Score

6/6

Financial Health Score 6/6

Short Term Liabilities
Long Term Liabilities
Debt Level
Reducing Debt
Stable Cash Runway
Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: MTPH's short term assets (£11.8M) exceed its short term liabilities (£1.8M).

Long Term Liabilities: MTPH's short term assets (£11.8M) exceed its long term liabilities (£620.0K).

Debt to Equity History and Analysis

Debt Level: MTPH is debt free.

Reducing Debt: MTPH has no debt compared to 5 years ago when its debt to equity ratio was 4.5%.

Balance Sheet

Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: MTPH has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: MTPH has sufficient cash runway for 1.5 years if free cash flow continues to grow at historical rates of 15.1% each year.

Discover healthy companies

Dividend

What is Midatech Pharma current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

Notable Dividend
High Dividend
Stable Dividend
Growing Dividend
Earnings Coverage
Future Dividend Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate MTPH's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate MTPH's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.

Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if MTPH's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if MTPH's dividend payments have been increasing.

Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.

Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as MTPH has not reported any payouts.

Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

2.1yrs

Average management tenure

CEO

Stephen Stamp (59 yo)

2.75yrs

Tenure

UK£328,867

Compensation

Mr. Stephen A. Stamp serves as Chief Financial Officer and Director of Midatech Pharma plc since September 9, 2019. He serves as Chief Executive Officer at Midatech Pharma plc since March 31, 2020 and serv...

CEO Compensation Analysis

Compensation vs Market: Stephen's total compensation ($USD399.62K) is about average for companies of similar size in the UK market ($USD334.17K).

Compensation vs Earnings: Stephen's compensation has increased whilst the company is unprofitable.

Leadership Team

Experienced Management: MTPH's management team is considered experienced (2.1 years average tenure).

Board Members

Experienced Board: MTPH's board of directors are considered experienced (7.5 years average tenure).

Ownership

Who are the major shareholders and have insiders been buying or selling?

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 55.4%.

Data	Last Updated (UTC time)
Company Analysis	2022/06/30 00:00
End of Day Share Price	2022/06/30 00:00
Earnings	2021/12/31
Annual Earnings	2021/12/31